PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Immune

KPV

Also written as: Lys-Pro-Val, Lysine-proline-valine, L-Lysyl-L-prolyl-L-valine, alpha-MSH(11-13), alpha-MSH (11-13) (free acid), MSH (11-13), ACTH-(11-13), KPV acetate

KPV is a chain of three amino acids taken from the end of a natural hormone; it has calmed inflammation in cell and mouse studies, but it has never been tested in a human trial and is not an approved medicine.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • KPV is three amino acids (lysine, proline, valine). They are the last three of a natural hormone called alpha-MSH. It is not an approved medicine.
  • In mice with colitis (bowel inflammation), KPV reduced inflammation in several studies. In lab dishes it damped inflammatory signals in gut cells and immune cells.
  • No human trial of KPV has been published or registered. In 2026 the FDA found no human exposure data for KPV by any route.
  • The main caution: safety in people is unknown. The FDA also found no animal toxicity studies and no studies of how the body absorbs or clears it.
  • How it works is not settled. The evidence suggests it does not act through the receptors that alpha-MSH itself uses.
  • It is not FDA-approved and is not on the list pharmacies may compound from. FDA staff proposed in May 2026 not to add it.
  • WADA does not name KPV, but its S0 class bans substances with no approval for human use, and no approval of KPV was found anywhere.

What it is

KPV is a very small peptide. A peptide is a short chain of amino acids, the building blocks of proteins. KPV has only three: lysine (K), proline (P) and valine (V). These are the last three amino acids of a natural hormone called alpha-melanocyte-stimulating hormone, or alpha-MSH. Alpha-MSH is 13 amino acids long and is cut out of a larger body protein called POMC. It acts on a family of docking sites on cells called melanocortin receptors. It is known for its roles in skin pigment and appetite, and it also damps inflammation in animal studies.

More on what it is and where it came from

Researchers became interested in KPV because, in animal and cell studies, this small end-piece appeared to keep the anti-inflammatory action of alpha-MSH without its effect on skin pigment. Since 1989 it has been tested in mice and rabbits and in cells grown in dishes, most often in models of bowel inflammation. The KPV used in research and sold today is made by chemical synthesis. It exists in more than one chemical form: the plain peptide (the free base), a salt form (the acetate), and, in some older studies, a version with chemically capped ends. These are not the same substance.

KPV is not an approved medicine. In a review dated 12 May 2026, the U.S. Food and Drug Administration (FDA) said it is not a component of any FDA-approved drug, has no official quality standard (pharmacopoeia monograph) in the United States, Europe or Japan, and that the European Medicines Agency lists no authorised product containing it. The FDA also found no published study in which a KPV product was given to people.

Alpha-MSH has been studied for decades as a hormone that affects pigment, fever and inflammation. In 1989, Hiltz and Lipton reported in the FASEB Journal that the end-piece of alpha-MSH, numbered 11 to 13, reduced ear swelling in mice. Earlier work had linked the three amino acids lysine-proline-valine to the fever-lowering action of alpha-MSH, and the authors suggested that new anti-inflammatory drugs might be built on them. In 2000 a group including Cutuli, Lipton and Catania reported that alpha-MSH and KPV slowed the growth of two microbes in the lab. In 2008 two separate groups (Dalmasso, Merlin and colleagues, funded by U.S. government grants; and Kannengiesser, Kucharzik and colleagues) each reported that KPV reduced colitis in mice. No published record was found of anyone taking KPV itself into human trials. A pharmacy company, Wells Pharmacy Network, nominated it to the FDA for use in compounded creams and gels and later withdrew the nomination.

How it is thought to work

Nobody has shown exactly how KPV works. The FDA wrote in 2026 that the molecular targets behind its effects 'remain unknown'. The natural hormone alpha-MSH works by switching on melanocortin receptors. It was first assumed KPV did the same, but most of the evidence points the other way. In lab tests KPV did not compete with alpha-MSH for its binding sites on mouse melanoma cells, and it did not bind the MC1 receptor on mouse immune cells or raise the messenger molecule (cyclic AMP) that these receptors normally produce. In mice, KPV still reduced inflammation in animals bred without a working MC1 receptor, and a drug that blocks two other melanocortin receptors did not stop it. The FDA summed this up by saying melanocortin receptors 'are unlikely to be the molecular targets' of KPV. The question is not fully closed: one cell study found that KPV triggered a calcium signal in hamster ovary cells engineered to carry the MC1 receptor.

More on how it works

Other ideas come from cell studies. In human gut cells and immune cells grown in dishes, KPV reduced the activity of NF-kappaB, a switch inside cells that turns on inflammation genes, and lowered the release of inflammatory messenger proteins. A 2008 study proposed that KPV gets into gut cells through PepT1, a transporter in the gut lining that normally carries very small peptides from digested food into cells. In that study, blocking the transporter with a competing peptide cancelled the effect of KPV. A later mouse study from the same group found that KPV had no significant effect on colitis-related tumours in mice bred without PepT1. A separate study in human airway cells suggested that KPV enters the cell nucleus and interferes with the movement of an NF-kappaB protein into it. Mouse work has also suggested KPV may block the effects of interleukin-1 beta, an inflammatory messenger.

All of this comes from cells and rodents. The FDA found no study, in animals or people, measuring how KPV is absorbed, how long it lasts in the body, or where it goes. In one lab study using donated human skin, KPV did not pass through intact skin in measurable amounts.

What is established in people

Nothing is established in people. No human trial of KPV has been published, and a search of ClinicalTrials.gov on 18 November 2026 found no registered trial of it. The FDA reached the same result in 2026: no clinical studies, no case reports and no human exposure data by any route. Two related molecules did reach early human testing, but they are not KPV and their results cannot be transferred to it. One is K(D)PT, a different three-amino-acid peptide, which was reported as well tolerated in a randomised phase 2a trial in ulcerative colitis in 2017. The other is CZEN-002, a larger peptide built from the KPV sequence, which a company announcement in 2004 said had been tried as a vaginal gel in 20 women with a yeast infection; no journal report of that study was found.

What the studies found

12 studies, human trials first. Each links to the paper or registry record.

  1. Review2026

    Evaluation of KPV-related Bulk Drug Substances (KPV (free base) and KPV acetate) for Inclusion on the 503A Bulk Drug Substances List

    The FDA found no clinical study and no human exposure data for KPV by any route, and concluded that 'potential safety risks associated with the use of KPV in humans are unknown'.

    Full finding, who was studied, and limits

    Who: FDA scientists searched the published literature, ClinicalTrials.gov and the FDA's own side-effect report databases for KPV, as a possible ingredient in compounded creams and gels for wound healing and inflammatory skin conditions.

    The FDA found no clinical study and no human exposure data for KPV by any route, and concluded that 'potential safety risks associated with the use of KPV in humans are unknown'. It found no animal studies of toxicity, cancer risk, effects on reproduction, or of how the body handles KPV. It said there was 'a lack of evidence to evaluate the effectiveness' of KPV for wound healing or inflammatory conditions. It also judged both chemical forms to be 'not well-characterized', partly because products are sold under inconsistent names. It proposed not adding KPV to the list of substances pharmacies may compound.

    Read with care: The FDA looked mainly at use on the skin, because that is what the nomination proposed. This is a staff review written for an advisory meeting, not a final decision; news reports say the advisory committee voted the other way. Some background statements in the document cite commercial websites.

    FDA briefing document for the Pharmacy Compounding Advisory Committee, dated 12 May 2026 · fda.gov

  2. Review2008

    Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases.

    The authors described alpha-MSH as acting through melanocortin receptors to damp inflammation in animal models of fever, skin inflammation, arthritis and inflammation of several organs.

    Full finding, who was studied, and limits

    Who: A review article by Brzoska, Luger, Maaser, Abels and Bohm. It gathered cell and animal studies of alpha-MSH and of two three-amino-acid peptides, KPV and a related one called KdPT. It is not a study of a defined group.

    The authors described alpha-MSH as acting through melanocortin receptors to damp inflammation in animal models of fever, skin inflammation, arthritis and inflammation of several organs. They noted that alpha-MSH also darkens skin, which could limit its use as a medicine, and presented KPV as an alternative that kept the anti-inflammatory effect in these studies without the pigment effect.

    Read with care: A review reports what earlier studies found; it is only as strong as those studies, which were in cells and animals. The abstract reports no human trial of KPV. The review also argues for a related peptide, KdPT, which is a different molecule.

    Endocrine Reviews · pubmed.ncbi.nlm.nih.gov

  3. Animal study2017

    Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis.

    Mice given the coated KPV particles lost less weight and recovered better than untreated mice with colitis.

    Full finding, who was studied, and limits

    Who: Male mice with DSS colitis, 5 per group, given KPV in nanoparticles coated with hyaluronic acid (a natural sugar chain) inside a gel, by tube into the stomach. Also mouse and human cell lines in dishes.

    Mice given the coated KPV particles lost less weight and recovered better than untreated mice with colitis. Their colon measurements and levels of the inflammatory messenger TNF-alpha did not differ markedly from those of healthy mice. In the dish, the coated particles sped up the closing of a gap made in a layer of human gut cells and were not toxic to the cells over 48 hours.

    Read with care: Mice and cells, not people. Small groups, male mice only, one colitis model. There was no group given plain KPV, so the study compares two particle designs and cannot say how plain KPV would do. Tissue damage was shown in pictures without scores. The text contains some inconsistencies in its methods. The authors described KPV as having no notable side effects, but the paper contains no human data.

    Molecular Therapy · pmc.ncbi.nlm.nih.gov

  4. Animal study2016

    Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model.

    In normal mice, KPV sharply reduced the number and size of colitis-related tumours.

    Full finding, who was studied, and limits

    Who: Mice given chemicals that cause colitis followed by colon tumours, with or without KPV in their drinking water; 5 to 6 per group. Normal mice were compared with mice bred without the PepT1 transporter, and with a second strain that develops bowel tumours for genetic reasons without inflammation.

    In normal mice, KPV sharply reduced the number and size of colitis-related tumours. In mice without PepT1, KPV made no significant difference, which supports the idea that KPV needs this transporter. In the genetic tumour model, KPV lowered a marker of gut inflammation but did not reduce tumours.

    Read with care: Mice, not people. The benefit was limited to tumours driven by chemically induced inflammation; there was no effect on tumours in the genetic model. The text describes the tumour results in words, with numbers only in figures. The authors wrote that further studies are needed. This study is not evidence that KPV treats or prevents cancer in people.

    Cellular and Molecular Gastroenterology and Hepatology · pmc.ncbi.nlm.nih.gov

  5. Animal study2010

    Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model.

    In the dish, KPV-loaded particles reduced inflammatory responses more than empty particles.

    Full finding, who was studied, and limits

    Who: Human gut-lining cells (Caco2-BBE) in dishes and mice with DSS colitis. KPV was packed into tiny particles (nanoparticles, about 400 nanometres across) and those were wrapped in a gel designed to break down in the colon. The abstract does not give animal numbers.

    In the dish, KPV-loaded particles reduced inflammatory responses more than empty particles. Mice given KPV-loaded particles were protected against the inflammation and tissue changes seen with DSS alone. The authors reported that KPV delivered this way worked at a concentration 12,000 times lower than KPV dissolved in water.

    Read with care: Mice and cells, not people. This is a test of an experimental delivery system that is not available as a product; it says nothing about plain KPV powders, capsules or creams. Animal numbers are not in the abstract.

    Gastroenterology · pubmed.ncbi.nlm.nih.gov

  6. Animal study2008

    PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.

    In the dish, very low concentrations of KPV reduced NF-kappaB activity and lowered the gene activity for an inflammatory messenger (IL-8) by about 35%.

    Full finding, who was studied, and limits

    Who: Two parts. First, human gut-lining cell lines (Caco2-BBE and HT29-Cl.19A) and a human immune cell line (Jurkat) in dishes. Second, female mice with colitis caused by one of two chemicals (DSS or TNBS), with KPV added to their drinking water; 5 to 10 mice per group according to the figure legends.

    In the dish, very low concentrations of KPV reduced NF-kappaB activity and lowered the gene activity for an inflammatory messenger (IL-8) by about 35%. Radio-labelled KPV was taken up by the cells, and a competing small peptide cancelled KPV's effect, which pointed to the PepT1 transporter. The gut cells carried two melanocortin receptors, but the authors concluded these did not explain the effect. In mice, KPV reduced weight loss and lowered a marker of white-cell build-up in the colon (myeloperoxidase) by about 50% in DSS colitis and about 30% in TNBS colitis, with lower levels of several inflammatory messengers.

    Read with care: Cells and mice, not people. The mouse experiments were short (2 to 8 days), used only female mice, and tested only sudden, chemically induced inflammation, which is an imperfect stand-in for long-term human bowel disease. KPV levels in blood or tissue were not measured. The evidence for PepT1 was indirect in this paper.

    Gastroenterology · pmc.ncbi.nlm.nih.gov

  7. Animal study2008

    Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.

    In DSS colitis, mice given KPV recovered earlier and regained more body weight, with fewer inflammatory cells in the colon wall and lower myeloperoxidase activity.

    Full finding, who was studied, and limits

    Who: Mice with colitis produced in two ways: by the chemical DSS, and by transferring a type of immune cell that causes bowel inflammation. Also mice bred without a working MC1 receptor, given DSS. A different research group from the one in the study above. The abstract does not give animal numbers.

    In DSS colitis, mice given KPV recovered earlier and regained more body weight, with fewer inflammatory cells in the colon wall and lower myeloperoxidase activity. In the cell-transfer model, treated mice also recovered and regained weight. In mice without a working MC1 receptor, all the animals given KPV were rescued from dying during colitis, which suggests the effect is at least partly independent of that receptor.

    Read with care: Mice, not people. The abstract gives no group sizes or effect sizes. Mouse colitis models are an imperfect stand-in for human Crohn's disease or ulcerative colitis.

    Inflammatory Bowel Diseases · pubmed.ncbi.nlm.nih.gov

  8. Animal study2003

    Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides.

    KPV reduced the number of white blood cells entering the inflamed area.

    Full finding, who was studied, and limits

    Who: Mice with a short-lived inflammation of the abdominal lining (peritonitis) set off by crystals or by an inflammatory messenger, given KPV, alpha-MSH or other melanocortin drugs by injection. Also mouse immune cells (macrophages) in a dish, and mice bred without a working MC1 receptor. The abstract does not give animal numbers.

    KPV reduced the number of white blood cells entering the inflamed area. A drug that blocks the MC3 and MC4 receptors did not stop this, and KPV still worked in mice without a working MC1 receptor. In the dish, alpha-MSH and a synthetic melanocortin drug (MTII) lowered the release of inflammatory messengers from macrophages, and MTII raised cyclic AMP; KPV did neither. The authors concluded that KPV is unlikely to act through melanocortin receptors and more likely interferes with interleukin-1 beta.

    Read with care: Mice, not people. A short model lasting hours, not a long-term disease. Animal numbers are not in the abstract. It shows what KPV probably does not do, without proving what it does.

    Journal of Pharmacology and Experimental Therapeutics · pubmed.ncbi.nlm.nih.gov

  9. Animal study1989

    Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH.

    The fragment reduced ear swelling, and larger amounts reduced it more.

    Full finding, who was studied, and limits

    Who: Mice given a chemical (picryl chloride) that makes the ear swell, treated beforehand with the 11 to 13 fragment of alpha-MSH, and compared with mice given salt water or a steroid. The abstract does not give the number of animals.

    The fragment reduced ear swelling, and larger amounts reduced it more. The authors noted that this end-piece was already believed to carry the fever-lowering action of alpha-MSH, and concluded that it may also have a general anti-inflammatory action on which new drugs could be based.

    Read with care: Mice, not people, and a single short-term skin test. Animal numbers are not in the abstract. The FDA's 2026 review grouped this paper with studies of a chemically capped (N-acetylated) version of the peptide, which is not identical to plain KPV.

    FASEB Journal · pubmed.ncbi.nlm.nih.gov

  10. Cell study2017

    Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin.

    On its own, KPV did not cross the skin in an amount the test could detect.

    Full finding, who was studied, and limits

    Who: Thin sheets of donated human skin mounted in lab equipment. KPV solution was placed on one side and the amount crossing was measured. No living people were involved. The abstract does not say how many skin samples were used.

    On its own, KPV did not cross the skin in an amount the test could detect. It crossed only when the skin was pierced with microneedles, when a small electric current was applied to drive it through (iontophoresis), or both. Compared with microneedles alone, the current raised the rate 8 times and the combination 35 times.

    Read with care: A lab test on removed skin, not a study of a cream in people. It measured movement of the peptide, not any effect on a skin condition. The FDA drew on this study in 2026 to say that poor skin penetration could limit both the risks and the usefulness of KPV applied to the skin.

    Journal of Pharmaceutical Sciences · pubmed.ncbi.nlm.nih.gov

  11. Cell study2001

    Effects of melanocortin peptides on lipopolysaccharide/interferon-gamma-induced NF-kappaB DNA binding and nitric oxide production in macrophage-like RAW 264.7 cells: evidence for dual mechanisms of action.

    All three peptides lowered nitric oxide production and reduced the movement of NF-kappaB into the cell nucleus.

    Full finding, who was studied, and limits

    Who: A mouse immune cell line (RAW 264.7) grown in dishes and stimulated to mimic inflammation, then treated with alpha-MSH or two of its fragments, including the 11 to 13 fragment (KPV).

    All three peptides lowered nitric oxide production and reduced the movement of NF-kappaB into the cell nucleus. In lowering nitric oxide, alpha-MSH and the KPV fragment were about equally strong, and both were stronger than the other fragment. The cells carried MC1 receptors. Alpha-MSH bound to them and raised cyclic AMP. The KPV fragment did not bind them, even at the highest concentration tested, and did not raise cyclic AMP. The authors proposed two separate mechanisms, one of which does not need the receptor.

    Read with care: A mouse cell line in a dish. It cannot show whether the same happens in a living animal or a person.

    Biochemical Pharmacology · pubmed.ncbi.nlm.nih.gov

  12. Cell study2000

    Antimicrobial effects of alpha-MSH peptides.

    Both peptides reduced the number of Staphylococcus colonies and reduced the survival of Candida and its ability to form the thread-like shape linked to infection.

    Full finding, who was studied, and limits

    Who: Lab cultures of a bacterium (Staphylococcus aureus) and a yeast (Candida albicans), exposed to alpha-MSH or to KPV. Also human white blood cells (neutrophils) in a dish.

    Both peptides reduced the number of Staphylococcus colonies and reduced the survival of Candida and its ability to form the thread-like shape linked to infection. The effects were seen across a wide range of concentrations. The peptides did not weaken the ability of human neutrophils to kill these microbes; killing was enhanced.

    Read with care: Microbes and cells in dishes only. No infected animal or person was treated. Killing microbes in a dish often does not carry over to treating an infection.

    Journal of Leukocyte Biology · pubmed.ncbi.nlm.nih.gov

Safety findings

  • No human safety data. The FDA wrote in May 2026 that neither the nomination nor its own search had turned up 'any clinical studies or human exposure data for KPV via any route of administration', and that the potential safety risks in humans 'are unknown'. It said it was 'particularly concerned about the lack of any human data'. Source: fda.gov
  • No side-effect reports on file, which is not the same as evidence of safety. The FDA searched its drug side-effect database and the medical literature up to 3 December 2025 and its food and supplement complaint system from 2004 to December 2025, and found no reports involving KPV. The FDA noted that reporting is voluntary and that compounding pharmacies generally do not report side effects to it. Source: fda.gov
  • No animal safety testing was found. The FDA identified no studies of single-dose toxicity, repeated-dose toxicity, damage to genes, effects on pregnancy and fertility, or cancer risk for either form of KPV. It also found no study of how KPV is absorbed and cleared, in animals or in people. Source: fda.gov
  • The mouse studies of colitis were designed to look for benefit, not harm. They reported weight, bowel inflammation and tissue appearance over days, and cell tests reported that KPV-loaded particles did not harm cell survival. These are not safety studies and say little about people. Source: pmc.ncbi.nlm.nih.gov
4 more safety findings
  • Theoretical concern, immune reaction and clumping: the FDA noted that peptides can trigger an immune response and can clump together (aggregate), and that clumping raises the risk of an immune response. No study has tested either for KPV. The FDA said there is 'insufficient data to conclude' that KPV does not carry these risks. This is a risk that could not be ruled out, not an effect seen in patients. Source: fda.gov
  • Product quality is a separate safety issue. The FDA said it has seen different salts and even different active molecules sold under the same common name, and that the lab certificates it reviewed for KPV gave no information on the identity of impurities, on clumped peptide, or on microbial testing. Source: fda.gov
  • The FDA's public summary of its concern reads: 'FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.' Source: fda.gov
  • A related but different peptide, K(D)PT, was described as well tolerated at all tested amounts in a randomised trial in people with ulcerative colitis. K(D)PT is not KPV (it is a different three-amino-acid peptide, related to a fragment of the inflammatory messenger interleukin-1 beta), so this does not show that KPV is safe. Source: pubmed.ncbi.nlm.nih.gov

Rules and status

Not an FDA-approved drug. As of 18 November 2026 it is not on the FDA's list of substances pharmacies may compound from (the section 503A bulks list). FDA staff proposed in May 2026 not to add it. KPV acetate is one of six peptides named in a draft enforcement-discretion policy from the U.S. Department of Health and Human Services (HHS), announced on 30 October 2026; that is not an approval and does not put it on that list.

The full history, with dates

Approval: no product containing KPV is FDA-approved. The FDA found no United States, European or Japanese pharmacopoeia standard for it and no product authorised by the European Medicines Agency. Category 2 and withdrawal: KPV was previously in 'Category 2' of the FDA's interim compounding policy, the group of nominated substances that may present significant safety risks. It now appears in the FDA's table of 'Bulk drug substances nominated but withdrawn', which the FDA describes as substances 'previously in category 2' whose nominations 'were withdrawn by the nominators'. The FDA's stated reason for KPV, quoted in full: 'FDA has not identified any human exposure data on drug products containing KPV administered via any route of administration. FDA lacks important information regarding any safety issues raised by KPV, including whether it would cause harm if administered to humans.' That FDA page is dated 22 April 2026. The FDA's category list dated 14 May 2026 shows KPV in no category. Advisory committee: on 16 April 2026 the FDA published a Federal Register notice calling a Pharmacy Compounding Advisory Committee meeting for 23 and 24 July 2026, with KPV on the agenda even though the nomination (from Wells Pharmacy Network) had been withdrawn. In a briefing document dated 12 May 2026, FDA staff concluded that the evidence 'weighs against' listing and wrote: 'we propose not adding KPV (free base) or KPV acetate to the 503A Bulks List.' A medical news outlet (Healio, 24 July 2026) reported that the committee voted 8 to 6 with one abstention, twice, in favour of adding the free base and the acetate. A committee vote is advice only, and as of 6 August 2026 the FDA's meeting page had posted no minutes or vote results. HHS policy: on 30 October 2026 HHS published a notice in the Federal Register (91 FR 68526) announcing a draft 'Enforcement Discretion Policy' for pharmacy compounding of certain peptides. The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public' and gave two weeks for public comment. The notice does not name the peptides; it points to the policy on hhs.gov (read from an Internet Archive capture of 15 November 2026). Its Appendix A names exactly six peptides: BPC-157, epitalon, KPV, MOTS-c, semax and TB-500. Appendix B limits the policy to KPV acetate in topical and oral dosage forms compounded from an ingredient with a certificate of analysis meeting the policy's conditions. The policy lists ten conditions, including a patient-specific prescription, a single active ingredient, a certificate of analysis from an FDA-registered manufacturer, reporting of serious side effects to the FDA, and, for any oral form, documentation that the formulation is adequately absorbed by mouth in humans. HHS gives three reasons for including KPV: historical use is now documented and quantified, including substantial single-ingredient use; lots of the acetate supplied to pharmacies now confirm its identity by mass spectrometry and report the endotoxin and microbial results the FDA found missing; and the FDA's safety conclusion 'reflects an absence of information rather than an observed signal', which HHS says the policy's conditions address. HHS also states that neither the Category 2 placement nor its removal changed KPV's status under section 503A, and that the advisory committee voted in favour of inclusion. According to the notice, the policy concerns state-licensed pharmacies, federal facilities and licensed physicians. Rulemaking: a search of the Federal Register on 18 November 2026 found no proposed or final rule adding KPV to the 503A list. Nothing here is a finding that KPV is safe or effective.

Source: fda.gov (source dated 2026-04-22)

In sport: Not named. KPV does not appear in the text or index of the WADA 2026 Prohibited List (in force from 1 January 2026) or the 2027 List (in force from 1 January 2027). Class S0 (Non-approved substances) prohibits at all times 'any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use'. No other section names KPV, and no approval of it for human use was found anywhere (the FDA reported none in the United States and no product authorised by the European Medicines Agency), so S0 applies and KPV is prohibited at all times. The 2027 List adds the word 'peptides' to the S0 examples, and WADA's explanatory note says: 'Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.' WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
KPV heals the gut and treats colitis, Crohn's disease or inflammatory bowel disease.In mice, several studies found that KPV reduced chemically induced colitis. No study has tested KPV in people with any bowel disease. The FDA found no human data at all in 2026. Source: pmc.ncbi.nlm.nih.gov
It is part of a hormone your body already makes, so it is natural and safe.The KPV sequence is the last three amino acids of the natural hormone alpha-MSH. The KPV that is sold is made synthetically. Being related to a body hormone does not establish safety: the FDA concluded that the safety risks of KPV in humans 'are unknown', and it found no toxicity studies in animals either. Source: fda.gov
Human studies show KPV works.There are none. No human trial of KPV has been published or registered. Trials sometimes cited in support tested other molecules: K(D)PT, a different three-amino-acid peptide tested in ulcerative colitis, and CZEN-002, a larger peptide built from the KPV sequence. Neither is KPV. Source: pubmed.ncbi.nlm.nih.gov
It works the same way as alpha-MSH, through melanocortin receptors.Probably not. In lab tests KPV did not bind the MC1 receptor or raise the signal that receptor produces, and in mice it still worked when melanocortin receptors were blocked or missing. The FDA wrote that its molecular targets 'remain unknown'. One cell study did find a receptor-linked signal, so the question is not fully closed. Source: pubmed.ncbi.nlm.nih.gov
It is antimicrobial and fights Candida and staph infections.In lab dishes, KPV reduced the growth or survival of Staphylococcus aureus and Candida albicans. No study has treated an infection in a person with KPV. Source: pubmed.ncbi.nlm.nih.gov
KPV cream treats psoriasis, eczema and wounds.No human study exists for any skin condition. The FDA said there is 'a lack of evidence to evaluate the effectiveness' of KPV for wound healing and inflammatory conditions. In a lab test on donated human skin, KPV did not pass through intact skin in measurable amounts. Source: pubmed.ncbi.nlm.nih.gov
It reduces tumour growth or treats colon cancer.One mouse study found fewer colitis-related colon tumours in mice given KPV. The same study found no reduction in tumours in a second, genetic mouse model. There are no human data. The FDA included a clinic web page making this claim as an example of how KPV is promoted. Source: pmc.ncbi.nlm.nih.gov
The FDA approved KPV (or made it legal) in 2026.It is not approved. FDA staff proposed not adding it to the pharmacy compounding list. What exists is a draft HHS enforcement-discretion policy, published 30 October 2026, that states it creates no rights and is not binding. KPV acetate is one of the six peptides named in its Appendix A. Source: hhs.gov
It is fine for tested athletes because WADA does not list it.WADA does not name KPV, but its S0 class prohibits any substance with no approval for human use that is not covered elsewhere on the list. From 2027 that class names peptides as an example, and WADA warns that a peptide need not be named to be prohibited. Source: wada-ama.org

What a genuine lab report should show

  • Identity by mass spectrometry: the measured mass should match the expected molecular weight of about 342.43 g/mol for the free base (formula C16H30N4O4), and the report should confirm the sequence Lys-Pro-Val.
  • The report should say exactly which form was tested: the free base, the acetate salt (the FDA gives 402.5 g/mol), or a version with capped ends. The FDA found a certificate for KPV whose title named one form and whose formula matched another, and notes that the same CAS number (67727-97-3) is used for both the free base and the acetate.
  • Purity by HPLC (a method that separates a sample into its components), with a limit and a result for total impurities and for the largest single impurity. The FDA pointed out that most public certificates for KPV show only a purity figure and say nothing about what the impurities are.
  • Amino acid analysis showing lysine, proline and valine in roughly equal parts, as on the certificate the FDA reproduced.
  • Peptide content, which is different from purity. The acetate-salt certificate the FDA reproduced listed acetate at about 20% and water at about 5% of the powder by weight, so the amount of actual peptide in a vial is lower than the powder weight.
  • Breakdown products: forced-degradation work cited by the FDA found that KPV breaks down to a ring-shaped by-product of lysine and proline (a diketopiperazine), plus free proline and valine. A careful report would show these were looked for.
  • Microbial quality (bioburden, and bacterial endotoxin for anything sterile) and a check for clumped peptide (aggregates). The FDA noted that none of the KPV certificates it saw covered these.
  • A lot-specific certificate: the results should be tied to the batch number on the vial, name the testing laboratory, and be dated.

How to read a lab report

What is not known

  • Does KPV do anything useful in people? No human trial has been published or registered for any condition.
  • Is it safe in people? There are no human data and, according to the FDA, no animal toxicity studies of any kind.
  • How does it work? Its molecular target is unknown. Most evidence points away from melanocortin receptors, but one cell study found a receptor-linked calcium signal, and the PepT1 transporter idea rests mainly on work from one research group.
  • Does KPV reach the bloodstream or the gut wall when swallowed, or the deeper skin when applied as a cream? No absorption study in animals or people was found, and a lab test on donated skin found no measurable passage through intact skin.
  • Is free KPV actually present in the human body as its own molecule? The sequence is the end of alpha-MSH, but I found no opened primary source measuring the free three-amino-acid peptide in human tissue. The FDA document's statement that it 'is naturally produced in the body' cites a clinic website.
  • Which chemical form did each study use? Natural alpha-MSH ends in an amidated valine, some studies used KPV with capped ends, and the abstracts often do not say. Results from one form may not apply to another.
  • The advisory committee vote of 23 July 2026. HHS states that the committee voted in favour of inclusion. The 8 to 6 with one abstention tally comes from a news report (Healio); the FDA's meeting page, current as of 6 August 2026, had not posted minutes.
  • Whether the HHS policy is now final. The notice calls it a draft, the comment period closed in mid-November 2026, and no later notice was found.
  • When exactly KPV was first placed in Category 2. The FDA page says only that it was 'previously in category 2'. HHS Appendix B (read from an Internet Archive capture of 15 November 2026) states that both forms were in Category 2 from September 2023 until 22 April 2026; no dated FDA record of the original placement was opened.
  • CZEN-002: I could not confirm from an opened journal source that the molecule in the 2004 company announcement is the same as the (CKPV)2 dimer described in academic papers, or that its human study was ever published.
  • The size of the K(D)PT trial: the PubMed abstract does not give the number of patients.

Sources

All 37 sources
  1. PubChem: Msh (11-13) / Lys-Pro-Val, CID 125672 (formula, weight, CAS, sequence, synonyms). pubchem.ncbi.nlm.nih.gov
  2. UniProt P01189: human pro-opiomelanocortin (alpha-MSH is positions 138 to 150, sequence SYSMEHFRWGKPV; ligand for MC1R, MC3R, MC4R and MC5R). uniprot.org
  3. FDA briefing document on KPV for the 23-24 July 2026 advisory committee, dated 12 May 2026. fda.gov
  4. FDA briefing document introduction for the 23-24 July 2026 meeting (KPV nomination withdrawn; FDA proceeding). fda.gov
  5. FDA: bulk drug substances that may present significant safety risks (page current as of 22 April 2026; KPV in the 'nominated but withdrawn' table). fda.gov
  6. FDA: 503A nominated substances by category, updated 14 May 2026 (KPV in no category). fda.gov
  7. FDA: 23-24 July 2026 Pharmacy Compounding Advisory Committee meeting page (current as of 6 August 2026; no minutes posted). fda.gov
  8. Federal Register, 16 April 2026, document 2026-07361: advisory committee meeting notice naming KPV. federalregister.gov
  9. Federal Register, 30 October 2026, 91 FR 68526: HHS enforcement discretion policy notice (does not name the peptides). govinfo.gov
  10. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
  11. ClinicalTrials.gov search for KPV, Lys-Pro-Val and lysine-proline-valine (18 November 2026: no trial of KPV). clinicaltrials.gov
  12. Brzoska et al. 2008, review of alpha-MSH and related tripeptides. pubmed.ncbi.nlm.nih.gov
  13. Hiltz and Lipton 1989, first report of anti-inflammatory activity of alpha-MSH(11-13) in mice. pubmed.ncbi.nlm.nih.gov
  14. Lyson et al. 1994, KPV did not compete for alpha-MSH binding sites on melanoma cells. pubmed.ncbi.nlm.nih.gov
  15. Mandrika et al. 2001, mouse macrophage-like cells; KPV fragment did not bind MC1 receptors. pubmed.ncbi.nlm.nih.gov
  16. Getting et al. 2003, mouse peritonitis; KPV unlikely to act through melanocortin receptors. pubmed.ncbi.nlm.nih.gov
  17. Elliott et al. 2004, KPV raised calcium in cells engineered with the MC1 receptor. pubmed.ncbi.nlm.nih.gov
  18. Dalmasso et al. 2008, PepT1 uptake of KPV; cells and mouse colitis (full text). pmc.ncbi.nlm.nih.gov
  19. Kannengiesser et al. 2008, KPV in two mouse colitis models. pubmed.ncbi.nlm.nih.gov
  20. Laroui et al. 2010, KPV nanoparticles in mouse colitis. pubmed.ncbi.nlm.nih.gov
  21. Land 2012, KPV in human airway cells (proposed block of NF-kappaB entry to the nucleus). pubmed.ncbi.nlm.nih.gov
  22. Viennois et al. 2016, KPV and colitis-associated tumours in mice (full text). pmc.ncbi.nlm.nih.gov
  23. Xiao et al. 2017, hyaluronic acid KPV nanoparticles in mouse colitis (full text). pmc.ncbi.nlm.nih.gov
  24. Cutuli et al. 2000, antimicrobial effects of alpha-MSH peptides in the lab. pubmed.ncbi.nlm.nih.gov
  25. Singh and Mukhopadhyay 2011, end fragments of alpha-MSH against Staphylococcus aureus in the lab. pubmed.ncbi.nlm.nih.gov
  26. Charnley et al. 2008, antibacterial action of capped KPV peptides in the lab. pubmed.ncbi.nlm.nih.gov
  27. Bonfiglio et al. 2006, alpha-MSH(11-13) and corneal wound healing in rabbits. pubmed.ncbi.nlm.nih.gov
  28. Pawar et al. 2017, KPV across donated human skin in the lab. pubmed.ncbi.nlm.nih.gov
  29. Bohm and Luger 2019, review asking whether melanocortin peptides could be wound-healing drugs. pubmed.ncbi.nlm.nih.gov
  30. RELATED MOLECULE, NOT KPV: Kucharzik et al. 2017, K(D)PT in ulcerative colitis, randomised phase 2a trial. pubmed.ncbi.nlm.nih.gov
  31. RELATED MOLECULE, NOT KPV: Mastrofrancesco et al. 2010, KdPT in human skin oil-gland cells (did not bind MC1R). pubmed.ncbi.nlm.nih.gov
  32. RELATED MOLECULE, NOT KPV: Gatti et al. 2006, the KPV dimer (CKPV)2, described as under clinical investigation. pubmed.ncbi.nlm.nih.gov
  33. RELATED MOLECULE, NOT KPV: Ji et al. 2013, (CKPV)2 in a rat model of Candida vaginitis. pubmed.ncbi.nlm.nih.gov
  34. RELATED MOLECULE, NOT KPV: company announcement by Zengen Inc., 25 May 2004, on CZEN-002 (republished press release, not a journal paper). news-medical.net
  35. WADA 2026 Prohibited List (S0 text; KPV not named). wada-ama.org
  36. WADA 2027 Prohibited List, published 21 September 2026 (S0 adds peptides as an example; KPV not named). wada-ama.org
  37. WADA 2027 Prohibited List: summary of major modifications and explanatory notes (S0 and peptides). wada-ama.org

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sent to your email, with a note when a compound page or its legal status changes.

Sign-up link not connected yet.